Evidence map›Paper›PMID 38630892›Full record

ArticleBlood cancer discovery2024

Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma.

Leo Meriranta, Selma Sorri, Kanutte Huse, Xiaonan Liu, Ivana Spasevska, Sadia Zafar, Iftekhar Chowdhury, Olli Dufva, Eerika Sahlberg, Luka Tandarić and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Blood cancer discovery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Leo MerirantaResearch Programs Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-6378-5381
Selma SorriResearch Programs Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID 0009-0004-4067-5536
Kanutte HuseDepartment of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.ORCID 0000-0001-9128-670X
Xiaonan LiuInstitute of Biotechnology, HiLIFE Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-9600-0536
Ivana SpasevskaDepartment of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.ORCID 0000-0003-4838-8617
Sadia ZafarResearch Programs Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-6340-1077
Iftekhar ChowdhuryInstitute of Biotechnology, HiLIFE Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-0360-6951
Olli DufvaHematology Research Unit Helsinki, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.ORCID 0000-0002-8084-0282
Eerika SahlbergResearch Programs Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID 0009-0002-1745-1468
Luka TandarićResearch Programs Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID 0009-0009-1431-2586
Marja-Liisa Karjalainen-LindsbergDepartment of Pathology, Helsinki University Hospital, Helsinki, Finland.ORCID 0000-0001-6728-2266
Marko HyytiäinenResearch Programs Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-3017-6862
Markku VarjosaloInstitute of Biotechnology, HiLIFE Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-1340-9732
June H MyklebustDepartment of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.ORCID 0000-0003-0394-9986
Sirpa LeppäResearch Programs Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-8265-511X
University of Helsinki · FIOslo University Hospital · NOHelsinki University Hospital · FI

Funding

Biomedicum Helsinki-säätiö (Biomedicum Helsinki Foundation)Emil Aaltosen Säätiö (Emil Aaltonen Foundation)Finnish Cancer OrganizationsFinnish Research Council 341280 and 357481Helsinki University HospitalIda Montinin Säätiö (Ida Montin Foundation)Orionin Tutkimussäätiö (Orion Research Foundation)Paolo FoundationSigrid Juséliuksen Säätiö (Sigrid Jusélius Stiftelse)
6 · The paper itself

Abstract

Pathomechanisms that activate oncogenic B-cell receptor (BCR) signaling in diffuse large B-cell lymphoma (DLBCL) are largely unknown. Kelch-like family member 6 (KLHL6) encoding a substrate-adapter for Cullin-3-RING E3 ubiquitin ligase with poorly established targets is recurrently mutated in DLBCL. By applying high-throughput protein interactome screens and functional characterization, we discovered that KLHL6 regulates BCR by targeting its signaling subunits CD79A and CD79B. Loss of physiologic KLHL6 expression pattern was frequent among the MCD/C5-like activated B-cell DLBCLs and was associated with higher CD79B levels and dismal outcome. Mutations in the bric-a-brac tramtrack broad domain of KLHL6 disrupted its localization and heterodimerization and increased surface BCR levels and signaling, whereas Kelch domain mutants had the opposite effect. Malfunctions of KLHL6 mutants extended beyond proximal BCR signaling with distinct phenotypes from KLHL6 silencing. Collectively, our findings uncover how recurrent mutations in KLHL6 alter BCR signaling and induce actionable phenotypic characteristics in DLBCL. Significance: Oncogenic BCR signaling sustains DLBCL cells. We discovered that Cullin-3-RING E3 ubiquitin ligase substrate-adapter KLHL6 targets BCR heterodimer (CD79A/CD79B) for ubiquitin-mediated degradation. Recurrent somatic mutations in the KLHL6 gene cause corrupt BCR signaling by disrupting surface BCR homeostasis. Loss of KLHL6 expression and mutant-induced phenotypes associate with targetable disease characteristics in B-cell lymphoma. See related commentary by Leveille et al. See related commentary by Corcoran et al.

Indexed as

Adaptor Proteins, Signal TransducingCD79 AntigensLymphoma, Large B-Cell, DiffuseReceptors, Antigen, B-CellSignal TransductionCarrier ProteinsCell Line, TumorHumansMicrofilament ProteinsMutationAdaptor Proteins, Signal TransducingCarrier ProteinsCD79 AntigensCD79A protein, humanCD79B protein, humanKLHL6 protein, humanMicrofilament ProteinsReceptors, Antigen, B-Cell

Identifiers

PMID38630892
PMCPMC11369598
OpenAlexW4394872337

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.